<DOC>
	<DOCNO>NCT00673010</DOCNO>
	<brief_summary>One effective treatment metastases thyroid cancer form radioactive iodine know 131-I . For 50 year , 131-I use find destroy thyroid cancer cell spread part body . In many case treatment destroy metastatic cell . However , patient appear work completely . This study design use slightly different form radioactive iodine ( call 124-I ) precisely predict amount radiation metastatic lesion receive . 124-I developed Memorial Sloan-Kettering 1950s use many medical center around world diagnostic study . It find safe effective finding metastatic lesion . The high resolution new PET scanner allow u carefully determine much radiation metastatic lesion receive . If 124-I accurately predict patient respond 131-I treatment avoid expose patient unnecessary radiation . For rest patient custom tailor 131-I dose destroy metastatic lesion .</brief_summary>
	<brief_title>Lesion Dosimetry With 124-Iodine Metastatic Thyroid Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Adult thyroid carcinoma patient total thyroidectomy , histology confirm MSKCC attend pathologist , radioiodine remnant ablation . Adult thyroid carcinoma patient previously demonstrate radioiodineavid metastasis undergo Thyrogenassisted dosimetry MSKCC . The patient physician planning administer 131I therapy persistent radioiodineavid metastases present . Men woman race , ethnicity , religious background eligible . All subject must measurable disease , document within previous six month ultrasonography ( US ) , MRI , noncontrast CT scan . Thyroid cancer patient metastasis . Thyroid cancer patient demonstrate metastasis concentrate radioiodine . Patients therapy active cancer . Anaplastic Medullary thyroid carcinoma . Age le 18 year . Patient receive therapeutic dose radioiodine within precede nine month eligible . Patients plan withdraw thyroid hormone prior dosimetry . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>124-IODINE</keyword>
	<keyword>I-131 METAIODOBENZ SULF ( MIBG )</keyword>
	<keyword>Thyroid</keyword>
	<keyword>Parathyroid</keyword>
</DOC>